FinDogFinDog
Monday, November 2, 2026Closing data · 4:00 PM ET
English
Log in

LLY

Lilly (Eli)NYSE · Pharmaceuticals · Health Care
Previous close
1,417.54
Change
0.00 / 0.00%
FinDog View
Bullish
52-Week Range ?
812.25 – 1,449.68
P/E (TTM) ?
50.2
Forward P/E ?
26.3
Based on consensus earnings for the next 12 months
Market Cap
$1.34T
1M
+24.04%
Volume / Avg Volume
5.3M / 2.5M
2.14× average · Volume on 10-30
Latest earnings analysisFY2026 Q2Reported 2026-08-05

Lilly Q2 2026: revenue up 48.0% to $22.97 billion, EPS $7.94

Lilly's second quarter was a clean beat: revenue of $22.97 billion, up 48.0%, and non-GAAP EPS of $8.38 against a $6.07 consensus. Read it with two caveats — $3.03 per share of acquired IPR&D charges sit inside those numbers, and the full-year EPS range was narrowed even as revenue guidance rose. The underlying franchise is accelerating; the accounting noise is not.

Read the full analysis →
Revenue$22.97BYoY +47.70%
EPS (non-GAAP)$8.38Beatest. $6.07
Next-quarter revenue guidance$86.00BYoY +274.30%
Next-day move+1.89%

Price History

Closing price · USD1M6M1Y5Y
8001000120014001600EFY26 Q2 EarningsEFY26 Q1 EarningsEFY25 Q4 Earnings2025-112026-022026-052026-082026-10

Historical P/E

Close ÷ trailing four-quarter EPS · Period median 42.01M6M1Y5Y
37.54042.54547.5502026-102026-102026-102026-102026-10

Recent Earnings

Click to read the FinDog analysis
PeriodReportedRevenueEPS Actual / Est.Next-Day MoveAnalysis

Next Earnings

Date and consensus from the earnings calendar; the analysis is generated automatically after the releaseEarnings Calendar →
Report date
2027-02-02
in 92 days · Pre-market
Consensus EPS
$10.20
Last quarter EPS $8.38
Avg. next-day move over the last 6 reports
±3.5%

Decision Panel

Trends · Valuation · Earnings reaction · Guidance credibility — all from company filings and market data
Valuation
P/E is at percentile 28 of its 5-year rangeCheap
5-year range 39.1 – 132.9 · Median 71.5
Last 4 quarters: $5.8B in buybacks + $6.0B in dividends, 0.88% of market cap combined
P/E (TTM)
50.2
P/B
39.6
P/S
16.8
Dividend Yield
0.75%
Earnings Reaction
Over the last 6 reports, the stock moved ±3.5% on average on the first trading day after, rising 4 times
Most recent +1.89%
Volatility & Correlation
1-year beta 0.21 · Correlation with S&P 500 0.08Low beta
Annualized volatility 35% vs. 13% for the S&P 500
Insider Trading
View all →
Last 90 days · Open-market buys and sells by officers and directors · Amounts in USD millions
Buy 0 · $0.00MSell 3 · $16.0MNet selling $16.0M
  • 08-17Jonsson PatrikEVP & President, LLY Int'lSell$7.6M6,500 shares · Avg price 1,175.10
  • 08-10Zakrowski Donald ASVP, Finance, & CAOSell$2.4M2,000 shares · Avg price 1,185.01
  • 08-07Hakim AnatEVP, GC & SecretarySell$6.0M5,000 shares · Avg price 1,190.00
Multi-Quarter Financial Trends
View all quarters →
Last 12 quarters · As reported by the company
QuarterRevenue ($B)YoYGross MarginOperating Income ($B)Net Income ($B)Free Cash Flow ($B)EPS
FY2026 Q324.40+38.6%83.9%—6.4511.407.22
FY2026 Q222.97+47.7%85.8%—7.1010.697.94
FY2026 Q119.80+55.5%81.9%—7.405.338.26
FY2025 Q419.29+42.5%82.5%—6.643.237.39
FY2025 Q317.60+53.9%82.9%—5.588.846.21
FY2025 Q215.56+37.6%84.3%—5.663.096.29
FY2025 Q112.73+45.2%82.5%—2.761.673.06
FY2024 Q413.53+44.7%82.2%—4.412.474.88
FY2024 Q311.44+20.4%81.0%—0.973.711.07
FY2024 Q211.30+36.0%80.8%—2.971.473.28
FY2024 Q18.77+26.0%80.9%—2.241.172.48
FY2023 Q49.35+28.1%80.9%—2.19-0.312.42

Peers

Largest by market cap in the sector · Latest quarterView Health Care sector →
TickerCompanyMarket CapP/ERevenue YoYGross Margin1MView